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SUMMARY 
   
Introduction: Rituximab-based B-cell depletion (BCD) therapy is effective in 
refractory RA and, although used to treat patients with refractory SLE in routine 
clinical practice, rituximab failed to meet the primary endpoints in two large 
randomised controlled trials of non-renal (EXPLORER) and renal (LUNAR) 
SLE. 
 
Areas covered: We review how BCD could be improved to achieve better 
clinical responses in RA and SLE. Insights into the variability in clinical 
response to BCD in RA and SLE, may help develop new therapeutic strategies. 
To this end, a literature search was performed using the following terms: 
rheumatoid arthritis, systemic erythematosus lupus, rituximab and B-cell 
depletion..  
 
 
Expert Commentary: Poor trial design may have, at least partly, contributed to 
the apparent lack of response to BCD in the  two RCTs of patients with SLE. 
Enhanced B-cell depletion and/or sequential therapy with Belimumab may 
improve clinical response at least in some patients with SLE 
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IMPROVING B-CELL DEPLETION IN RHEUMATOID ARTHRITIS AND 
SYSTEMIC LUPUS ERYTHEMATOSUS  
 
 
1. Introduction 
Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are two 
systemic autoimmune diseases that arise from a complex interplay of genetic 
and environmental factors. 
The fundamental role of B-cells in the pathogenesis of RA and SLE has been 
reviewed, previously, and autoantibodies are characteristically associated with 
both RA and SLE 1, 2. It has been suggested that interaction between B cells 
and T cells perpetuates a “vicious cycle” of inflammation 1, 2. B cells can act as 
antigen presenting cells providing signals to T cells, which in turn provide “help” 
to other B cells through the delivery of cytokines and cell-surface ligands 3-5. 
Based on this, it could be hypothesised that elimination of either B cells or T 
cells should break the vicious cycle of inflammation, thereby, restoring a 
disease-free state, at least temporarily. Early studies in the 1990s, centred on 
the consideration that T cells played the dominant role, targeted T-cells. 
However, the results were disappointing in both RA and SLE  6, 7. Alternatively, 
B-cell targeting as a therapeutic option for RA was first proposed in the mid 
1990s founded on the hypothesis that autoantibodies, such as Rheumatoid 
Factor may in turn promote the survival of B cells, thus, propagating chronic 
inflammation in RA 8.  
 
2. Why were B-cells targeted in Rheumatoid Arthritis and Systemic Lupus 
Erythematosus? 
 5 
Targeting of B lymphocytes is of particular interest since B-cells play a major 
role in the pathogenesis of RA and SLE. B-cells develop from pluripotent stem 
cells in the bone marrow each expressing B-cell receptors with unique 
immunoglobulin variable region. Their maturation and activation processes 
occur as they migrate through the blood to perifollicular, germinal-centre and 
memory compartments in the lymph nodes and spleen and finally, as plasma 
cells, to the bone marrow. Delivery of survival and trophic signals such as cell-
surface ligands (such as vascular cell-adhesion molecule 1), or soluble factors, 
such as B-cell activating factor (BAFF, also known as BLyS) appear to be 
important for B-cell survival and maturation 9. Autoantibody production by 
pathogenic B- lineage cells may be sustained by long-lived plasma cells 10. In 
addition to antibody-dependent mechanisms, B cells also act as antigen-
presenting cells and co-stimulate T Cells and other inflammatory cell types 5.  
In RA, leukocytes infiltrate the synovial compartment contributing to synovitis. 
Even though T cells are abundant in the synovial milieu, direct targeting of T 
cells by cyclosporine or other T cell depleting agents has shown limited or no 
efficacy 11. The synovium of RA patients contains abundant myeloid cells and 
plasmacytoid dendritic cells, whose cytokines, HLA class II and co-stimulatory 
molecules are essential for T-cell activation and antigen presentation. Synovial 
B cells are mainly part of T-cell-B-cell aggregates which are supported by 
expression of factors such as ‘A proliferation-inducing ligand’ (APRIL), BAFF, 
and chemokines 11. As key factors of humoral adaptive immunity, these 
molecules constitute potential treatment targets for RA, discussed later.  
In SLE, several studies have focused on the role of anti-dsDNA antibodies in 
lupus nephritis. An interesting proposition is that the binding of antibodies to 
dsDNA itself is not the most critical determinant of tissue damage. Instead, 
extracellular double-stranded DNA appears mainly in the form of nucleosomes, 
as fragments of chromatin released by apoptotic cells and that anti-dsDNA 
antibodies bind these circulating nucleosome forming antibody-nucleosome 
complexes, which in turn bind the renal glomerular basement membrane 
triggering complement-mediated glomerulonephritis. This process may be the 
result of a “charge interaction”, where once anti-nucleosome complexes have 
formed in the circulation, the histones (part of nucleosome), being positively 
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charged, bind to the negatively charged components of the glomerular 
basement membrane (GBM). Thus, histones in effect act as a bridge between 
the anti-DNA/nucleosome antibodies and the GBM. This is known as the 
“histone-bridge theory” 12. Therefore, anti-dsDNA antibodies may mediate tissue 
damage by direct antibody- and complement-mediated cytotoxicity.   
These observations indicating a key role of B cells in propagating inflammation 
in RA and SLE, provide the rationale for targeting B cells in patients with RA 
and SLE 1, 3. 
 
 
 
 
 
3.B-cell depletion agents 
3.1 Rituximab as B-cell Depletion Agent in Autoimmune Disease 
Rituximab (RTX) is a chimeric monoclonal antibody that selectively binds the 
target antigen, CD20, and induces B-cell depletion. The safety and efficacy of 
its use in B cell malignancies resulted in licensing for the treatment of non-
Hodgkin Lymphoma 13. CD20 is expressed on B lymphocytes from the pre-B 
stage to the mature B stage, but not plasma cells 1, and therefore, treatment 
with rituximab would directly target only CD20+ B-cells.  
Edwards and Cambridge pioneered B-cell depletion therapy in 1999 for the 
treatment of RA14. Following the successful pivotal phase III study 15, rituximab 
was approved by National Institute for Health and Care Excellence (NICE) in 
2007. Isenberg and colleagues led studies on B-cell depletion therapy with 
rituximab for the treatment of Lupus 16. In 2004, the first phase I/II dose 
escalation trial of rituximab in SLE patients with active disease reported a 
favourable safety profile and promising clinical efficacy 17.  Although widely 
used in routine practice for the treatment of refractory SLE, with many case 
reports published indicating its utility 18, 19, rituximab did not meet endpoints in 
two randomized controlled trials: LUNAR and EXPLORER 20, 21. However, these 
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trials have been criticised for their poor design 22 23, 24. See later for more 
detailed discussion. 
 
3.2 Rituximab - Risk and Benefit Consideration: 
The use of rituximab in combination with immunosuppressants has raised 
concerns about increased risk of serious infection. However, most of the side 
effects reported with the use of rituximab were mild respiratory and urinary 
infections25. A significant reduction in autoantibody levels after B-cell depletion, 
namely rheumatoid factor (IgM, IgG and IgA isotypes) and antibodies to 
citrullinated peptides occur in contrast to a small reduction in total 
immunoglobulins levels and antibodies to pneumococcal-polysaccharide 10. 
Albert et al. have reported that response to immunisation following BCD with 
rituximab may be impaired in patients with SLE 26. Therefore, vaccination 
against influenza and pneumococcus prior to B-cell depletion is recommended 
27.  In our cohort of patients with SLE, we have recently described that low 
serum immunogloblulin levels after rituximab therapy seems to be largely 
restricted to the IgM isotype particularly in those receiving concomitant and/or 
sequential therapy with mycophenolate mofetil 28. Although rare, late-onset 
neutropenia has been reported with Rituximab27. Therefore, careful monitoring 
of patients with optimal dosage of immunosuppressants such as 
mycophenolate mofetil is essential to minimise the risk of infections after BCD 
with rituximab. 
Infusion-related reactions, mostly mild and manageable, associated with 
rituximab were reported in 20-40% of patients and premedication with 
antihistamine and methylprednisolone may help reduce the risk of infusion-
related reactions 16, 27.  
Progressive multifocal leukoencephalopathy (PML) has been reported after 
treatment with rituximab in patients with RA who had other comorbidities 29  and, 
also in patients with SLE treated with conventional immunosuppressants alone 
27. Thus, the absolute risk of PML associated with rituximab appears to be low.  
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3.3 Rituximab in Rheumatoid Arthritis: 
In 1999, the first pilot study of rituximab-based B-cell depletion therapy was 
initiated at University College London Hospital to treat patients with refractory 
RA 14. The length of benefit from B-cell depletion was related to the dose of 
rituximab, with shorter responses at low rituximab dose. These early studies 
demonstrated preliminary safety and efficacy of rituximab in RA 30 and informed 
the design of the pivotal phase III randomized, double-blind, controlled study for 
patients with RA 15. The regimen used in this study was two doses (1000 mg) of 
rituximab given 2 weeks apart, with premedication including a single 100 mg IV 
methylprednisolone and oral prednisolone (60 mg on day 2 and days 4 to 7, 30 
mg per day on day 8 to 14). Patients considered to be responders were 
retreated at or just before predicted relapse. This study showed that rituximab 
was effective in methotrexate-refractory RA 15. Almost 80% of subjects showed 
benefit and a significant proportion of patients achieved major benefit as 
assessed by ACR50 criteria15.  
A significant improvement was noted in extra-articular features such as 
subcutaneous nodules, vasculitis, anaemia and amyloidosis 30, 31. Edwards et at. 
described a mean time to retreatment of 20 months, with most of patients 
previously refractory to standard disease-modifying antirheumatic drugs being 
satisfactorily controlled by methotrexate, sulphasalazine, or leflunomide for at 
least 1 year 31. Clinical response in patients with RA lasted the period of B-cell 
depletion, which typically lasts 7–8 months1. B-Cell repopulation occurs with a 
immature phenotype, as seen after bone marrow transplantation or in umbilical 
cord blood 32. 
Repeated treatment with rituximab in RA resulted in reduction of serum C-
reactive protein (CRP) levels from 50-100 mg/L to less than 2 mg/L (reference 
range < 5 mg/L) and, clinical improvement and reduction in CRP were closely 
correlated with decrease in antibody levels 1. Furthermore, almost 50% of 
patients achieved clinical benefit that persisted even after repopulation of B 
cells, with the longest recorded period of improvement being 42 months31. 
Serum RF levels fell over a period of months, with IgG RF decreasing by 60% 
and antibodies to citrullinated peptides also decreased, becoming undetectable 
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in some cases 10. In the UCL RA patient cohort, clinical relapse has invariably 
been preceded by a detectable rise in autoantibodies10. A potential resistance 
mechanism of rituximab therapy though is that the underlying 
immunopathological process might be reactivated through signals from 
autoantibodies produced by long-lived plasma cells, which are not targeted by 
rituximab 31.  
 
3.4 Rituximab in SLE: 
Leandro et al reported the first open uncontrolled study of rituximab for SLE 
patients in 2002 16. Since then, several groups have reported on the efficacy of 
rituximab treatment in SLE patients with an impressive clinical response in 171 
(91%) of 188 adults with active, multi-organ SLE refractory to corticosteroid and 
immunosuppressive therapy 33. Looney and colleagues reported in their phase 
II study about the safety and efficacy of rituximab 17. In the uncontrolled studies, 
two rituximab regimens were used: two 1000 mg doses 2 weeks apart and 375 
mg/m2 for 4 weeks with the latter regimen showing a higher rate of response 
with 4 weeks regimen (94 vs 83%, p= 0.048). In a systematic review of 300 
patients with SLE from 21 studies with a follow-up period ranged from 3 months 
to over 36 months, Gregersen and Jayne observed that  eGFR < 60 
mL/min/1.73 m2 and nephrotic syndrome were associated with poor prognosis 
34. Therefore In patients with nephrotic syndrome, rituximab may be excreted 
more rapidly and more frequent doses of rituximab may be required. 
The response to B-cell depletion is remarkably variable between patients with 
SLE, with respect to the degree and duration of BCD, clinical response, 
duration of remission and relapse 35. Treatment with rituximab is associated 
with a reduction in anti-dsDNA and anti-nucleosome antibody levels, but no 
change is seen in anti-ENA antibodies 36. These findings suggest that anti-
dsDNA and anti-nucleosome antibodies, at least in a proportion of patients, are 
secreted by short-lived plasma cells, whereas anti-ENA antibodies are secreted 
by long-lived plasma cells 10. 
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Vital et al. described that effectiveness of B-cell depletion after Rituximab 
infusion in 39 SLE patients, using highly sensitive flow cytometry 37. They 
reported a significant reduction from baseline BILAG, major clinical response 
and partial clinical response rates of 51% and 31%, respectively. Fifty percent 
of the patients relapsed after 6-18 months. B cells were detectable in peripheral 
circulation in 21 patients after 2 infusions of rituximab, which included all 7 
nonresponders. Memory B cell and plasmablast frequency in peripheral blood 
at 26 weeks after rituximab was significantly higher in patients with earlier 
relapse versus patients with later relapse 37.  
Unexpectedly, the two randomized clinical trials (LUNAR [19] and EXPLORER 
[10]) investigating the safety and efficacy of rituximab failed to meet their 
primary endpoints. The apparent lack of response to rituximab in these two 
trials was attributed to poor design 23, particularly concomitant therapy with high 
doses of corticosteroids,  which may have interfered with the detection of 
clinical response attributable to rituximab specifically 33. However, LUNAR trial 
post-hoc analysis also showed a trend toward clinically relevant benefit in 
Africa-American and Hispanic patients with lupus nephritis with none of the 
patients treated with rituximab requiring rescue therapy with cyclophosphamide 
38. Further, post-hoc analyses revealed improvements in clinical and laboratory 
parameters, including anti-dsDNA antibody and serum C3 levels 24. Moreover, 
B-cell depletion clinical trials on Lupus Nephritis patients may need a longer 
follow-up given the data from a long-term follow-up study showing a significant 
number of patients achieve complete response during the second year of 
follow-up 39.  
Conventional standard of care for patients with SLE who have renal 
involvement includes corticosteroids, the prolonged use of which at high doses 
is associated with irreversible adverse effects such as diabetes, hypertension, 
weight gain and osteoporosis. Therefore, Lightstone et al proposed a rituximab 
based steroid sparing regimen to treat patients with lupus nephritis 
demonstrating remarkable efficacy 40. Isenberg and co-workers at UCLH, 
employed similar treatment regimen to treat SLE patients with a short duration 
of diagnosis whose principal clinical features were non-renal, again revealing 
steroid-sparing effect of rituximab 41. The results of this study showed that B-cell 
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depletion is effective when used early and can reduce  long-term steroid burden 
(6 months cumulative mean post-B-cell depletion 1287.3 mg vs 2834.6 mg of 
matched controls). Recently, Lightstone and her colleagues have reported data 
from the first 50 consecutive patients with biopsy-proven active International 
Society of Nephrology/Renal Pathology Society (ISN/RPS) class III, IV, or class 
V LN, treated with RITUXILUP protocol without long-term oral steroids. They 
reported that B-cell depletion at the time of diagnosis enabled 48 out of 50 
patients to avoid the use of maintenance oral steroids at 2 years of follow-up 42. 
Disappointingly, owing to recruitment difficulties, a randomised non-inferiority 
open multicentre trial, entitled RITUXILUP (NCT01773616) established to 
investigate the validity of rituximab-based steroid-sparing protocol for treating 
patients with SLE with refractory lupus nephritis has been discontinued. 
Therefore, a better understanding of the underlying reasons for the observed 
discrepancy in the efficacy of rituximab between individuals with SLE and, also 
between uncontrolled and controlled studies, may provide insights to develop 
strategies to target B cells more effectively.  
 
3.5 Variability in Biologic Response to Rituximab 
3.5.1 Rituximab Resistance vs Refractory Disease  
It is recognized that even effective depletion as measured in peripheral blood 
does not always correlate with clinical response 37. As previously suggested by 
our group, to understand these discrepancies better it is important to distinguish 
inadequate clinical response despite effective depletion as “refractory disease”, 
and not achieving effective depletion as “rituximab resistance” 35. The latter 
could be explained by insufficient dose or increased drug clearance, but also to 
resistance of B-cell clones to depletion mechanisms induced by rituximab. 
However, failure to achieve clinical response despite effective depletion may 
occur because the disease is not B-cell dependent for perpetuation. These 
important concepts led us to hypothesize that patients who do not achieve 
clinical response but are effectively depleted (“refractory disease”) and who do 
not reveal any evidence of early repopulation may not benefit from further B-cell 
targeted therapies. In contrast, at least some patients from the group with poor 
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clinical response who did not achieve effective sustained depletion (“rituximab 
resistance”) may benefit from other B-cell depletion agents or treatment 
regimens 35.  
Another important factor to consider is the potential consequences of BCD on 
IL-10 secreting B cells or Bregs. Our laboratory has shown that the frequency 
and/or function of Bregs, as assessed in in vitro studies, appears to be 
important in both RA 43 and SLE 44. However, to our knowledge as discussed in 
previous sections, better clinical response to rituximab is observed in patients 
with RA and SLE who achieve complete and durable B-cell depletion and poor 
response is associated with incomplete B-cell depletion 37, 45. In RA, clinical 
response to rituximab appears to relate to the degree of B-cell depletion 46 and 
that poor clinical response to rituximab may be improved by delivering an extra 
dose of rituximab 47. Nonetheless, further in vivo studies would provide our 
understanding of the clinical relevance of Bregs in the context of clinical 
response to BCD.  
 
3.5.2 Response to treatment 
In the initial UCL cohort of RA patients the time to relapse from repopulation of 
B cells varied from 0 to 17 months 32. Repopulation of the peripheral blood 
occurs predominantly with naive mature and transitional B cells, similar to the 
situation after bone marrow transplantation. As previously reviewed, prolonged 
clinical response in RA and in SLE seems to be associated with delayed 
reconstitution of peripheral blood CD27+ memory B cells, whereas shorter 
responses correlates with repopulation with higher levels of memory B cells 35. 
Changes in serum autoantibodies also seem to correlate with clinical response. 
It is recognized for example that seropositive RA patients respond better than 
seronegative RA patients. In SLE prolonged response was also associated with 
baseline seronegativity for autoantibodies against extractable nuclear antigens 
(36), whereas patients with high dsDNA tended to flare earlier. Recently, we 
have described a clear disparity in fluctuations of the levels of serum IgG and 
anti-dsDNA autoantibodies in our cohort 28. Taken together, these findings 
suggest that incomplete B-cell depletion and repopulation predominantly with 
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memory B-cells and plasma cells is clinically relevant. In this context, it has 
been suggested that repopulation with IL-10 secreting B cells (regulatory B 
cells) may help achieve durable clinical response after rituximab, perhaps by 
facilitating a better balance between effector and regulatory B-cell 
subpopulations at repopulation after rituximab. 
Clinical response to rituximab does not seem to differ between RA patients of 
different ethnicities. In contrast, a subgroup analysis in the LUNAR study of 
patients with lupus nephritis, Hispanic and African-American patients showed a 
more favourable response to rituximab than Caucasians.   
The development of human antichimeric antibody (HACA) are described in both 
RA and SLE 15, 17, 48. Interestingly, patients with autoimmune diseases are more 
likely to develop HACAs than patients with lymphoma (<1% in B-cell 
malignancies, 5% in RA 15 and 26% in SLE 20. However, it does not seem to 
influence the clinical response in RA and SLE significantly.  
 
The potential of rituximab pharmacokinetics as a potential cause for the 
variability in B-cell depletion in RA and SLE has also been investigated. Serum 
rituximab levels, despite the same dosing regimen employed, were significantly 
lower in patients with SLE compared to RA. In RA, there is no evidence for 
correlation between serum rituximab levels and clinical response. At both 1 and 
3 months after rituximab therapy, serum rituximab levels were highly variable in 
patients with RA and SLE 49. In addition, serum rituximab levels achieved in RA 
patients were >9 fold greater compared to patients with SLE, at both 1 and 3 
months after treatment with rituximab. Patients with RA, but not SLE, achieving 
complete depletion had significantly higher serum rituximab levels than those 
with incomplete B-cell depletion. The lack of correlation between rituximab 
levels and CD19+ B cell counts in peripheral circulation raise the possibility of 
intrinsic resistance of some B cells to cytotoxic effects of rituximab 49. Thus, the 
underlying reasons for the inter-individual variability in rituximab levels within 
each disease category remain elusive. 
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4. How can we improve B-cell depletion  
4.1 Reflections on defining B-cell depletion 
B-cell depletion as measured by arbitrarily defined peripheral CD19+ cells <5-10 
cells/l in most studies does not consistently correlate with clinical response. In 
contrast, the use of highly sensitive flow cytometry (HSFC) to count B-cells in 
both RA and SLE show that the degree of B-cell depletion correlates with 
clinical response, suggesting the utility of HSFC in predicting outcome 37. 
Another important finding of studies with HSFC was that peripheral B-cell 
depletion was incomplete in 18% of patients with RA and 54% of patients with 
SLE, comprising of plasmablasts/plasma cells and memory B cells. Taken 
together, these findings suggest that incomplete depletion and repopulation 
predominantly with memory B cells and plasma cells is detectable by HSFC. 
 
 
 
4.2 Anti-CD20 mAbs: how do they differ and what’s the relevance in RA 
and SLE? 
Historically, rituximab has set the bench-mark for anti-CD20mAbs and to date, 
rituximab remains the most successful anti-CD20 mAb that has been used in 
clinical practice, in both B cell malignancies and autoimmune disease. However, 
as discussed earlier, the variability in clinical response to rituximab in both RA 
and SLE highlights the patient’s unmet need. To this end, research has focused 
on increasing the efficiency of anti-CD20 mAbs in an effort to improve the 
clinical response, particularly in the significant minority of patients that respond 
less well to rituximab. Although research in this field was driven by the need for 
improved B-cell depleting therapies in B cell malignancies 50, given the 
increasing use of B-cell depletion therapy in a range of autoimmune disease it 
is clinically relevant to understand whether, if any, B-cell depletion agents, 
based on their ‘mechanistic selling points’, offer specific advantages for 
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considering their use in autoimmune disease such as RA and SLE, reviewed 
recently 51.  
Anti-CD20 mAbs evoke B-cell cytotoxicity through antibody-dependent cell 
cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), 
complement-mediated cellular cytotoxicity (CDC) and induction of direct cell 
death 50, illustrated in Figure 1. In order to overcome the potentially significant 
problem of human anti-chimeric antibodies (HACAs) associated with the use of 
chimeric anti-CD20 mAbs such as rituximab, humanized anti-CD20 mAbs such 
as Ocrelizumab and Ofatumumab were tested in clinical trial settings in RA and 
SLE (Ocrelizumab only). 
 
4.2.1 Consideration of fully humanized anti-CD20 
Ocrelizumab is a humanized anti-CD20 monoclonal antibody studied in clinical 
trials for RA and SLE. In RA, ocrelizumab was effective in reducing signs, 
symptoms and joint damage when added to methotrexate (two regimens used: 
200 mg and 500 mg x 2 every 6 months). However, its use was associated in 
RA patients with a dose dependent increased risk of serious infections. Two 
clinical trials were initiated to test its safety and efficacy in SLE. These studies 
used a higher dose of ocrelizumab compared to RA trials (either 400 or 1000 
mg x2 at entry with repeat, single dosing every 4 months). The BEGIN study for 
nonrenal SLE patients was discontinued early. The BELONG study for 
proliferative lupus nephritis compared 1000 mg or 400 mg ocrelizumab at 1 day 
and 15 days, then repeated with a single dose every 4 months (on a 
maintenance therapy of high-dose glucocorticoids and either mycophenolate 
mofetil or cyclophosphamide dosed according to EUROLUPUS protocol). This 
trial was also terminated early due to a greater risk of serious infection in the 
ocrelizumab patients mainly in the Far East 23 .  
Ofatumumab, another humanized anti-CD20 mAb that binds a unique epitope 
on the smaller of the two extracellular loops of CD20 distinct from that of 
rituximab, has remarkably slow off-rate (i.e dissociative half-life) and evokes 
potent CDC. These two features may explain its capacity to lyse rituximab-
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resistant chronic lymphocytic leukaemia targets 52. Furthermore, it was shown 
to be effective in patients with RA who failed conventional disease modifying 
therapy 53 and also in a patient with SLE, who had a prior history of serum-
sickness like reaction to rituximab 54. 
Thus, although there are no directly comparative data on their efficacy in both 
RA and SLE relative to that achieved by rituximab, the available data thus far, 
does not indicate that simply switching to humanized anti-CD20 mAbs improves 
efficacy of B-cell depletion therapy with these agents in RA and SLE. However, 
humanized anti-CD20 mAbs such as ocrelizumab and ofatumumab are useful in 
individual patients with a history of serum sickness like reaction 54 and/or 
evidence of high titre HACAs associated with rituximab.  
Other developments in anti-CD20 mAbs have focused on improving the 
efficiency of anti-CD20 mAbs by increasing the affinity for target antigen CD20 
and/or FcRs on effector cells. For example, AME-330, has been engineered 
with improved affinity for both CD20 and also FcRIII 55. The results of clinical 
trials of AME-330 in SLE are awaited.  
Mechanistically, there are two types of anti-CD20 mAbs. Type I anti-CD20 
mAbs like rituximab, are efficient at recruiting complement for cellular 
cytotoxicity, owing to their ability to cluster CD20:anti-CD20 mAb complexes on 
B cell surface. However, an undesirable consequence of clustering CD20:anti-
CD20 mAb complexes is their interaction with the inhibitory FcRIIb on B cells, 
which increases the potential for internalization of these complexes leaving less 
amount of anti-CD20 mAb remaining bound to the surface of B cells for 
engaging with FcRIII-bearing effector cells 56, 57. Type II anti-CD20 mAbs such 
as Obinutuzumab does not appear to cluster CD20 and are therefore less 
rapidly internalized compared to rituximab, as shown in malignant and healthy B 
cells, in vitro 57. Obinutuzumab was also generated to bear an afucosylated Fc 
portion that engages FcRIIIa with a greater affinity than that of glycosylated 
anti-CD20 mAbs. Thus, the type II nature and afucosylated Fc portion may 
explain why obinutuzumab is less efficient at evoking CDC, but more efficient at 
recruiting FcR-bearing effector cells to induce ADCC and ADCP. Based on, the 
safety and superior clinical responses in patients with chronic lymphocytic 
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leukaemia (a B-cell malignancy) treated with obinutuzumab compared to those 
treated with rituximab 58, and the observations that, in vitro, B cells from patients 
with RA and SLE internalize rituximab impairing its efficiency of B-cell 
depletion59, obinutuzumab has recently entered clinical trials for the treatment of 
refractory SLE to explore whether the mechanistic advantages afforded by 
obinutuzumab will translate into clinical benefit in patients with refractory SLE.  
It is not entirely clear as to what effector mechanisms are important for attaining 
good clinical response to BCD with rituximab. The association between higher 
affinity FcRIIIa genotype and better clinical response to rituximab suggests that 
ADCC appears to be a clinically relevant effector mechanism in both RA 60  and 
SLE 61. Beyond this, to our knowledge, very little is known about the clinical 
relevance of which effector mechanism is important for improving clinical 
response to rituximab. Further, disease-associated factors need careful 
consideration when evaluating the efficiency and resistance of anti-CD20 
monoclonal antibodies, as discussed recently 51. 
 
4.3 Blocking B-cell activating factor 
BAFF (also known as B-cell activating factor, BLyS) is a cytokine of TNF family, 
which binds to three receptors on B lymphocyte’s surface: BLyS receptor 3 
(BR3), transmembrane activator-1 and calcium modulator and cyclophillin 
ligand-interactor (TACI), and B-cell maturation antigen (BCMA). The 
suppression of the binding of BLyS to BR3 causes cell apoptosis and inhibition 
of the maturation of B-cells 62. Therefore BAFF is considered an important 
target to manipulate B cell function and/or survival.  
The safety and efficacy of Belimumab, a monoclonal antibody that antagonises 
BAFF, was evaluated in two clinical trials involving more than 800 patients in 
each trial: BLISS 52 63 and BLISS 76 64. Both trials met their primary endpoints 
and at least some secondary endpoints 24 . An important caveat is that the most 
common features of patients in these large Phase III trials were skin and joint 
manifestations and patients with prior exposure to B-cell depletion were 
excluded. The primary endpoint of the studies was a composite score, the SLE 
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Responder Index, which comprises a fall in Systemic Lupus Erythematosus 
Disease Activity Index of 4 points, no new BILAG A or B scores, and no change 
in the physician’s global assessment. It met the primary endpoint with a 10% 
and 14% absolute response difference over placebo. Interestingly, post-hoc 
analysis have shown significant reduction in naive and activated B-cells, as well 
as plasma cells, in belimumab-treated patients 65. These patients also 
experienced significant reductions in IgG and autoantibodies and improvement 
in C3 and C4 levels, whereas preexisting antipneumococcal or anti-tetanus 
toxoid antibody levels were not substantially affected 65. 
Atacicept is a fusion protein that antagonises the effects of BAFF and another 
cytokine known as APRIL. Both BAFF and APRIL levels are increased in SLE 
patients, suggesting that dual blockade by atacicept may be more potent than 
blockading BAFF alone; it has also the benefit of targeting long-lived plasma 
cells. A randomised Phase II/III trial of atacicept in non-renal SLE failed to 
achieve primary endpoint (reducing the number of SLE patients who had a new 
flare) in the 75 mg arm compared with placebo. However, in a post-hoc analysis 
patients in the higher dose arm (150 mg) who completed the study showed 
significantly fewer flares and time to first flare 66. A significant reduction in anti-
dsDNA antibodies, plasma cells and the mean IgG concentration in the 
atacicept groups was observed in this study. A separate study of renal patients 
was stopped because three patients given atacicept developed significant 
infections 67. However, more detailed analysis of the data showed these 
infections were linked to significant hypogammaglobulinemia induced by the 
mycophenolate given two weeks before any atacicept was administered. 
Phase II trials of Blisibimod, an anti-BAFF monoclonal antibody, have 
encouraging results and there is an ongoing Phase III trial with a deliberate 
focus on patients with more active disease 64.  
Tabalumab is a fully human IgG4 monoclonal antibody that binds and 
neutralises both membrane and soluble BAFF. Two phase III studies, 
ILLUMINATE-1 68 and ILLUMINATE-2 68, evaluated the efficacy and safety of 
subcutaneous doses of tabalumab plus standard-of-care versus placebo plus 
standard-of-care in patients with active SLE. Patients received a loading dose 
 19 
of 240 mg at week 0 and followed by 120 mg every 2 weeks, 120 mg every 4 
weeks or placebo. ILLUMINATE 1 did not meet efficacy endpoints. However, 
the primary outcome (achieving SLE Responder Index 5 improvement at week 
52) was met with in the group receiving 120 mg every 2 weeks in ILLUMINATE 
2, although it failed to met other key secondary endpoints 68. An important point 
to consider though is the design of ILLUMINATE-1 stipulated that new, 
increased or decreased standard of care medications would define a patient as 
non-responder, whereas in ILLUMINATE 2 only new or increased medications 
determined non-response 68. In both studies, significant reductions in total B-
cells, immunoglobulins and anti-dsDNA antibodies levels and increases in C3 
and C4 were observed with tabalumab. 
 
4.4) Combining anti-CD20 and anti-B-cell activating factor antibodies 
Cambridge and colleagues have shown that rituximab-based BCD leads to 
significant increases in serum BAFF levels in both RA 69 and SLE 70. An 
important observation though is that the low B-cell counts was associated with 
the high serum BAFF levels 70, due to simply relative lack of BAFF-receptor 
expressing B cells.  During an 18-month follow-up period, a low BAFF state 
after B-cell depletion appeared to be associated with a favourable clinical 
outcome. High BAFF levels after B-cell depletion and repopulation of peripheral 
B cells distinguished those patients with relapsing disease from those remaining 
in remission. Further, serum BAFF levels during relapse after B-cell depletion 
with Rituximab were significantly elevated in comparison with disease flare prior 
to treatment and correlate positively with levels of anti-dsDNA antibodies (prior 
and post treatment) 70. Therefore, BAFF may have a role in disease flare after 
B-cell depletion, hence, special attention should be given to sequential B-cell 
depletion, where increasing BAFF levels and rising dsDNA antibody levels may 
promote a disease flare even at low B-cell numbers 70. 
BEAT-LUPUS, a randomised clinical trial is being undertaken at University 
College London Hospital and other centres, it will evaluate the potential of 
belimumab to prevent flares in patients with SLE after rituximab-based B-cell 
depletion therapy. 
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4.5 Other targets to achieve B-Cell depletion 
Epratuzumab is a monoclonal antibody that targets CD22 antigen on B cells. 
CD22 is considered to influence B-cell activation and migration.  Dorner et al. 
published the first open label study in 2006 in which 14 patients with moderately 
active SLE were treated with four doses of i.v. epratuzumab (360 mg/m2) with 
antihistamine (but no steroids) as premedication, fortnightly. Total BILAG 
disease scores improved by ≥ 50% at 6, 10, 18 and 32 weeks post treatment 
(77, 71 and 38%, respectively). At the final 32-week evaluation, statistically 
significant improvement in total BILAG score was observed, with 15% of the 
patients achieving ≥ 50% improvement 71. The results of two Phase II RCTs 
where Epratuzumab significantly improved disease activity in patients with 
moderate-to-severe SLE 72, 73. These studies were successfully viewed as a 
proof of concept in the efficacy of Epratuzumab in treating SLE and have led to 
further Phase III studies. However, first data from two phase 3 RCT multicenter 
studies of epratuzumab in active, moderate-to-severe SLE failed to meet its 
endpoints [(EMBODY 1™ (SL0009, NCT01262365) and EMBODY 2™ 
(SL0010, NCT01261793)] 74. 
 
Anti-CD19 targeting is potentially a new possible treatment, justified by its role 
in the threshold for BCR activation and by directly targeting autoantibody-
secreting plasmablasts, plasma cells and early B-cells not targeted by anti-
CD20 therapy. Anti-CD19 targeting is being discussed as a new possible 
treatment, justified by its role in the threshold for BCR activation and by directly 
targeting autoantibody-secreting plasmablasts, plasma cells and early B-cells 
not targeted by anti-CD20 therapy. Successful targeting of CD19+ plasma cells 
in patients with SLE may target diverse range B-cell subpopulations compared 
to anti-CD20 mAbs. Immunological consequences of anti-CD19 therapy in vivo 
would also therefore warrant careful evaluation 75. 
 
5. Expert commentary:  
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B-cell depletion was clearly a sensible aproach for patients with RA and SLE 
since B-cells have major roles in their aetiopathogenesis. Rituximab, introduced 
in 1997 for the treatment of non-Hodgkin’s lymphoma has established itself as a 
widely-used and effective treatment in rheumatoid factor positive and/or anti-
CCP positive RA patients. (It is however less successful in seronegative RA). Its 
success has been based on successful clinical trials following the original 
observations of Edwards and Cambridge. In contrast Rituximab, although 
considered to be useful by phyisicians who have used it, has not been as widely 
utilised in SLE because two major clinical trials did not meet primary end points. 
However, it is evident that trial design played a major part in this apparent lack 
of response. Several post hoc analyses have shown “hints and allegations” 
about its potential utility. Rituximab is now being used in a clinical trial in 
combination with Belimumab[Office1] which, having been approved by the FDA 
in 2012 was approved very recently by NICE. Belimumab blocks the B-cell 
activating factor BAFF. There are data to suggest that in some lupus patients 
following Rituximab there is a rise in BAFF which provides the academic 
rationale to treat patients with Rituximab followed by Belimumab.  
Fully humanised B-cell depleting agents eg Ocrelizumab and Ofatumumab have 
been tried in clinical trials of patients with RA and SLE but to date are not widely 
used. A clinical trial of Ocrelizumab was stopped because of concerns about 
infections although these seemed to have been largely confined to patients 
living in the Far East. 
 
6. Five-year view:  
The use of B-cell depletion in rheumatoid arthritis is secure and the key 
questions here relate to whether newer forms of anti-CD20 mAbs will be even 
more effective with even fewer side-effects. Determining whether or not B-cell 
depletion has a part to play in the treatment of lupus is critically dependent upon 
the success of further clinical trials and this in turn depends upon improving 
clinical trial design and in ensuring the training of testing physicians wishing to 
participate in lupus clinical trials. 
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The newer anti-CD20 mAbs are focused on improving the efficicency of B-cell 
depletion. These so-called type II anti-CD20 mAbs (eg Obinutuzamab) do not 
appear to lead to the clustering of CD20 molecules on the B-cell surface and 
are therefore less rapidly internalised compared to Rituximab (a type I anti-
CD20 monoclonal). Studies using this drug have been shown to be successful 
in chronic lymphocytic leukaemia and it is hoped that trials just started in lupus 
will also be successful. 
In addition to giving anti-CD20 mAbs on their own, there is increasing interest in 
the notion that combinations of monoclonals will prove to be even more 
successful and there are high hopes for the Rituximab and Benlysta trials going 
on in the UK and United States. However this is one crystal ball which remains 
very hard to read! 
7. Key Issues 
 B cells are fundamental in the pathogenesis of rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE). 
 B-cell depletion therapy (BCDT) has been successfully used to treat RA. 
 Although used to treat patients with refractory SLE in clinical practice, 
rituximab failed to proove its efficacy on two randomized controlled trials, 
probably owing to poor trial design. 
 Newer anti-CD20 monoclonals may prove more eficient than rituximab at 
inducing B-cell depletion. 
 Elevated B-cell activating factor levels after BCDT are associated with 
high anti-dsDNA antibodies, which provides the rationale for sequential 
therapy with Belimumab after treatment with rituximab. 
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Figure 1 - Schematic illustrating rituximab mechanisms of action. Rituximab 
binds to CD20+B cells triggering effector mechanisms: antibody-dependent cell 
cytotoxicity, complement-dependent cellular cytotoxicity and direct cell death. B 
cells opsonised with rituximab are recognised as ‘foreign’ attracting complement 
deposition and/or engagement with FcR-bearing effector cells that induce 
cellular cytotoxicity. Not shown in the fiugure is another important effector 
mechanism antibody-dependent cell phagocytosis.  
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